Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Next Previous
X
Search
Trial Profile

A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMX 001 (Primary) ; Cisplatin
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms BMX-HN
  • Sponsors BioMimetix

    • Most Recent Events

    • 09 Jan 2023 The sequential assignment is added in the trial. The study Assessing safety of drug in which patients Experience Grade 4 or 5 also by escalating doses of BMX-001 and Each dose will be reported separately. The Incidence Radiation-induced Mucositis by Clinician Scoring is reduced from 12 months to 6 months, hence protocol was amendment.
    • 16 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 26 Aug 2020 Planned End Date changed from 1 Feb 2020 to 1 Feb 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top